stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 2 | +91.5% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (12) | (102) | (123) | (243) | (125) | (162) | (125) | (287) | +47.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (12) | (102) | (123) | (243) | (125) | (162) | (125) | (287) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.10) | (4.83) | (1.85) | (1.99) | (0.83) | (0.69) | (0.44) | (0.95) | +28.0% | ||||||
| Cash flow | — | — | — | (0.09) | (1.55) | (1.20) | (0.85) | (0.67) | (0.47) | (0.34) | (0.31) | +25.3% | ||||||
| Capex | — | — | — | 0.00 | (1.84) | (0.28) | (0.14) | (0.14) | (0.10) | (0.03) | (0.49) | n/m | ||||||
| Free cash flow | — | — | — | (0.09) | (3.39) | (1.49) | (0.98) | (0.82) | (0.56) | (0.37) | (0.81) | +27.3% | ||||||
| Book value | — | — | — | 0.42 | (5.42) | 6.89 | 3.38 | 2.11 | 1.81 | 1.15 | 1.16 | +18.3% | ||||||
| Shares, m | — | — | — | 119 | 21 | 66 | 122 | 150 | 234 | 284 | 296 | +15.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (10) | (33) | (80) | (103) | (101) | (109) | (95) | (98) | +44.7% | |||||
| Capex | — | — | — | (1) | (39) | (19) | (17) | (22) | (23) | (10) | (154) | +58.9% | ||||||
| Free cash flow | — | — | — | (10) | (71) | (98) | (120) | (123) | (132) | (105) | (252) | +47.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 48 | 106 | 394 | 396 | 295 | 277 | 258 | 245 | +32.2% | |||||
| Net debt | — | — | — | (47) | (119) | (414) | (436) | (312) | (298) | (276) | (269) | +34.5% | ||||||
| Shareholders’ equity | — | — | — | 50 | (114) | 457 | 412 | 317 | 423 | 325 | 362 | +36.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (43.38) | (112.74) | (39.21) | (47.78) | (27.48) | (36.01) | (27.72) | (65.25) | +15.7 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (185.60) | 0.00 | (2,039.97) | (89.66) | (179.37) | (203.13) | (179.4) pt | ||||||
| ROE | — | — | — | 18.87 | 159.36 | (71.68) | (55.92) | (34.33) | (43.68) | (33.27) | (78.25) | (52.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 123 | 129 | 126 | 103 | 103 | — | (4.3%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Erasca, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CGON CG Oncology, Inc. | $5.7B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| SRRK Scholar Rock Holding Corporation | $5.5B | — (loss-making) | — (loss-making) | +605.03% (above 0%: growing) | n/m | +8.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PTCT PTC Therapeutics, Inc. | $5.5B | — (loss-making) | 42.2× | +69.57% (above 0%: growing) | n/m | +90.28% (above 0%: growing) | 93.39% | 7.02% | Compare |
| MANE Veradermics Incorporated | $5.4B | — (loss-making) | — | — | n/m | −8.81% (below 0%: shrinking) | — | 0.00% | Compare |
| COGT Cogent Biosciences, Inc. | $5.1B | — (loss-making) | — (loss-making) | −69.41% (below 0%: shrinking) | n/m | −42.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRSP CRISPR Therapeutics AG | $4.7B | — (loss-making) | — (loss-making) | +1,325.08% (above 0%: growing) | n/m | −6.36% (below 0%: shrinking) | 100.00% | (1,026.48%) | Compare |
| TVTX Travere Therapeutics, Inc. | $4.7B | — (loss-making) | — (loss-making) | +36.22% (above 0%: growing) | n/m | +6,379.75% (above 0%: growing) | 98.72% | (30.33%) | Compare |
| ERAS Erasca, Inc. | $4.6B | — (loss-making) | — | — | n/m | −4.67% (below 0%: shrinking) | 0.00% | 0.00% | |
| DNTH Dianthus Therapeutics, Inc. | $4.6B | — (loss-making) | — (loss-making) | +205.56% (above 0%: growing) | n/m | −65.91% (below 0%: shrinking) | 100.00% | (4,832.40%) | Compare |
| Median of peers | $5.3B | — | — | +205.56% | — | −7.58% | 93.39% | (15.16%) |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
14.20%
Jonathan E. Lim, M.D.
11.60%
Entities affiliated with Frazier Life Sciences
7.30%
Entities affiliated with Venrock Healthcare Capital
5.20%
T. Rowe Price Investment Management, Inc.
5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement